Leading Indian pharmaceutical companies have amassed substantial funds amounting to approximately ₹30,000 crore, earmarked for strategic acquisitions aimed at expanding their presence in new markets.
Mankind Pharma has green lighted allocation of ₹7,500 crore and has raised its borrowing limit to ₹12,500 crore in anticipation of both significant and minor acquisition opportunities. The potential target is Bharat Serums and Vaccines.
Cipla’s management is open to exploring sizable acquisitions within India to bolster its therapy segment and reinforce its dominant position. Additionally, the company is actively seeking product-specific opportunities in the United States.
As reported by blitzindiamedia.com, the surplus cash reserves held by pharmaceutical firms have witnessed a steady rise since FY21, reaching a current estimate of around ₹28,100 crore, which is equivalent to fifteen percent of the capital invested.
